The Dublin-based maker of Botox and other specialty medications and procedures closed at $145.12 after the firm posted a loss of $12.83 a share for the quarter. Adjusted for one-time gains and costs, the company posted per-share earnings of $4.29 a share, above analysts' expectations of $4.15.
Allergan posted revenue of $4.08 billion in the period, which also topped analysts' forecasts. Analysts surveyed by Zacks Investment Research had expected revenue of $4 billion. For the full year, the company reported that its loss widened to $5.1 billion, or $15.26 a share. Revenue came in at $15.79 billion.
For the current quarter, Allergan said it expects its per-share earnings to range from $3.40 to $3.60 a share. Analysts surveyed by Zacks had been forecasting adjusted earnings per share of $3.66.
The company also said it expects revenue in the range of $3.4 billion to $3.55 billion for the first quarter. Analysts surveyed by Zacks had been anticipating revenue of $3.61 billion. Allergan expects full-year revenue in the range of $15 billion to $15.3 billion.
Technical analyst Bruce Kamich of Real Money, our premium site for active investors, wrote in a note just ahead of Tuesday's report that Allergan "has been in a downtrend from the middle of 2015, and I do not yet find enough technical evidence that is has ended. AGN could rally in the next few months, but that may not be enough to reverse the longer-term decline." You can read his full analysis here.